Publication | Closed Access

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

Hannah StudyBreast OncologyOncologyBreast CancerAdjuvant TrastuzumabCancer TreatmentMedicineRadiation OncologyPhase 3